Eye-specific mitochondrial diseases are a group of rare disorders closely associated with the ocular function and structure, typically resulting from mutations in mitochondrial DNA. These conditions can lead to visual impairment, paralysis of eye muscles, and other ocular symptoms. Protheragen is globally recognized as a leader in the field of mitochondrial disease research. With our extensive expertise and advanced platform, we are committed to providing top-notch research services for eye-specific mitochondrial diseases.
Autosomal Dominant Optic Atrophy
Autosomal dominant optic atrophy (ADOA) is an uncommon mitochondrial genetic disorder characterized by progressive deterioration of vision. Patients typically experience the onset of visual impairments during childhood or adolescence, which gradually progresses to optic nerve degeneration and eventual loss of vision.
Chronic Progressive External Ophthalmoplegia
Chronic progressive external ophthalmoplegia (CPEO) is an uncommon mitochondrial disorder characterized by impaired ocular motility and ptosis. Patients may experience restricted eye movement, nystagmus, and a gradual paralysis of ocular motion.
Leber Hereditary Optic Neuropathy
Leber Inherited optic neuropathy (LHON) is a rare genetic disorder that affects the optic nerve, resulting in progressive bilateral blindness. This condition typically manifests during early adulthood and exhibits a higher prevalence among males compared to females.
Neuropathy Ataxia Retinitis Pigmentosa Syndrome
The neuropathy, ataxia, and retinitis pigmentosa syndrome, also known as NARP syndrome, is an uncommon mitochondrial genetic disorder characterized by the presence of neuropathy, ataxia, and retinitis pigmentosa.
Our Services
Protheragen' dedicated team of experts offers a comprehensive range of research services, encompassing fundamental mechanistic studies and advanced therapeutic development. Whether you are investigating Eyes-specific Mitochondrial Diseases or exploring innovative treatment modalities, we provide the expertise, resources, and collaborative spirit required to propel your research forward.
Therapeutics Development Services for Alpers Disease
The focus of our research lies in the development of pharmaceuticals targeting eye-specific mitochondrial diseases, encompassing drug screening and the advancement of drug delivery systems.
We provide an extensive array of services tailored to the development of molecular drugs.
Our Advantages
The services and support provided by Protheragen are comprehensive in addressing the research and therapeutics development of eye-specific mitochondrial diseases. Please feel free to contact us for further information regarding these specific diseases and the range of services we offer.
